Accuray (NASDAQ: ARAY) bets on personalized cancer care with University of Wisconsin research alliance
Read More General business news Babcock (LSE: BAB) absorbs Type 31 charge but keeps FY27 outlook intact Babcock’s Type 31 charge hurts profits, but cash flow and buybacks keep the turnaround alive. The execution risk now moves to FY27. bySrinathMay 17, 2026